Avedro is a commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses. Co.'s proprietary Avedro Corneal Remodeling Platform is comprised of its KXL and Mosaic systems, each of which delivers ultraviolet A light, and a suite of proprietary single-use riboflavin drug formulations, which, when applied together to the cornea, induce a biochemical reaction called corneal collagen cross-linking. Co.'s KXL system in combination with its Photrexa drug formulations is indicated for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. The AVDR average annual return since 2020 is shown above.
The Average Annual Return on the AVDR average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AVDR average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AVDR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|